US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

28.71

0.0000

Volume:4

Turnover:117

Market Cap:2.58M

PE:- -

High:28.71

Open:28.71

Low:28.71

Close:28.71

52wk High:28.93

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.40

T/O Rate:0.00%

Dividend:0.92

Dividend Rate:3.20%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live

Femasys announces FDA approval of FemBloc modular premarket approval application

Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances

Amylyx Phase 3 data support FDA approval, says Citi

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Cogstate posts record FY26 results and deepens AI-enabled CNS trial platform

Cogstate lifts profit and doubles dividend as clinical trials revenue surges

This Healthcare Stock Could Jump Nearly 40%

Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

PDS Biotech Reports Second Quarter 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NVIB/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":28.7085,"timestamp":1790947800145,"preClose":28.7085,"halted":0,"volume":4,"delay":0,"changeRate":0,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"10-02 09:34:29 EDT","open":28.7085,"high":28.7085,"low":28.7085,"amount":117,"amplitude":0,"askPrice":29.22,"askSize":100,"bidPrice":29.15,"bidSize":600,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.7085,"nav":28.281,"aum":2545349.47,"dividendRate":0.031984,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.38,"preClose":28.7085,"latestTime":"16:10 EDT","volume":6,"amount":172.251,"timestamp":1790885404178,"change":-0.3285,"changeRate":-0.011443,"amplitude":0},"volumeRatio":0.395839},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.395839,"shares":90001,"dividePrice":0.9182,"high":28.7085,"amplitude":0,"preClose":28.7085,"low":28.7085,"week52Low":24.54,"pbRate":"--","week52High":28.93,"institutionHeld":0,"latestPrice":28.7085,"committee":0.714286,"eps":0,"divideRate":0.031984,"volume":4,"delay":0,"ttmEps":0,"open":28.7085,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":28.0966,"twentyDayClose":28.4889},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660835402","title":"Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2660835402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660835402?lang=en_us&edition=fundamental","pubTime":"2026-08-20 16:08","pubTimestamp":1787213283,"startTime":"0","endTime":"0","summary":"An announcement from Arctic Bioscience AS ( ($DE:9TD) ) is now available. Arctic Bioscience AS, a biotech company specializing in pharmaceutical an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","NVIB","XBIX","IEIH","LNGR","AS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660028408","title":"Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2660028408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660028408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:43","pubTimestamp":1787200984,"startTime":"0","endTime":"0","summary":"Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for its F...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4585","PINK","NVIB","PSCH","TBXU","BK4588","IBB","MRNY","SYNB","GDOC","GNMX","BMED","XLVX","LFSC","LABU","IYH","FRTY","MEDI","TECB","RSPH","BBP","IEIH","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479252","title":"Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479252?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:31","pubTimestamp":1787182297,"startTime":"0","endTime":"0","summary":"Memphasys Ltd ( ($AU:MEM) ) has shared an announcement. Memphasys Ltd, an Australian reproductive biotech specialist, is commercialising its Felix ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/memphasys-secures-vietnam-registration-for-felix-system-triggers-first-major-order?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/memphasys-secures-vietnam-registration-for-felix-system-triggers-first-major-order?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","MEM","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421716","title":"European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421716","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421716?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:18","pubTimestamp":1787152727,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.68% to 1,973.64 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm BioNTech  and biopharmaceutical company Grifols , which advanced 24% and 5.6% respectively. They were followed by semiconductor company Sequans Communications  and biopharmaceutical company argenx , which rose 3.3% and 3% respectively.The decliners from continental Europe were led by internet browser company Opera  and biotech firm Evaxion , which fell 7.9% and 6% respectively. They were followed by accommodations booking site Trivago  and telecommunications company Nokia , which were down 4.3% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics  and mining company BHP Group , which increased 9.2% and 4.5% respectively. They were followed by software firm Endava  and biopharmaceutical company Bicycle Therapeutics , w","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IEUR","LU2324357040.USD","PUK","SNN","TRVG","LU0109394709.USD","IE00B2B36J28.USD","EPV","LU0006061336.USD","BK4585","BNTX","IE00B4R5TH58.HKD","NOK","LFGY","BK4548","XBIX","BK4588","DAVA.AU","EVAX","OPRA","TBXU","COAL","GRFS","LNOK","LU0648005311.SGD","NVIB","BK4141","TRIB","BDRX","IBB","IE00BJT1NW94.SGD","LU0823416689.USD","BHP.AU","AFG","ARGX","FMED","BK4117","LU1983260115.SGD","BCYC","SLX","LU0300736062.USD","SQNS","IE0009355771.USD","AUTL","BK4547","IE00BMPRXN33.USD","LU0889565916.HKD","DAVA","BHP","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","RSPH","TBXU","PSCH","IEIH","IDNA","BBP","SYNB","BMED","GDOC","NVIB","LABU","MRNX","IYH","IBB","BK4585","LFSC","XLVX","BK4584","BK4082","BK4588","MEDI","FEMY","FRTY","PINK","GNMX","MRNY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499847","title":"Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499847","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660499847?lang=en_us&edition=fundamental","pubTime":"2026-08-19 01:02","pubTimestamp":1787072575,"startTime":"0","endTime":"0","summary":"Vivoryon Therapeutics AG ( ($NL:VVY) ) has issued an announcement. Vivoryon Therapeutics N.V., a Germany-based clinical-stage biotech listed on Eur...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","XBIX","BK4195","NVIB","BK4229","AGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660595493","title":"Amylyx Phase 3 data support FDA approval, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2660595493","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660595493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:05","pubTimestamp":1787061936,"startTime":"0","endTime":"0","summary":"Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BMED","TECB","BBP","IYH","RSPH","MRNY","LFSC","IEIH","XLVX","LABU","GDOC","FRTY","GNMX","BK4585","TBXU","PINK","SYNB","AMLX","IBB","MRNX","NVIB","BK4007","MEDI","PSCH","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660608394","title":"Propanc Biopharma starts finalization of clinical trial protocol for PRP study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660608394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660608394?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:50","pubTimestamp":1787057418,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its fir...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NVIB","HYLG","GDOC","PPCB","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660443063","title":"Cogstate posts record FY26 results and deepens AI-enabled CNS trial platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2660443063","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660443063?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:49","pubTimestamp":1787006950,"startTime":"0","endTime":"0","summary":"Cogstate Ltd ( ($AU:CGS) ) has shared an update. Cogstate Ltd is a science-led clinical trial endpoint specialist focused on central nervous system...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cogstate-posts-record-fy26-results-and-deepens-ai-enabled-cns-trial-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cogstate-posts-record-fy26-results-and-deepens-ai-enabled-cns-trial-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AIPO","IDNA","MEDX","NVIB","ARTY","BK4135","GDOC","HYLG","CHAT","AGIX","VTHR","QTOC","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660306364","title":"Cogstate lifts profit and doubles dividend as clinical trials revenue surges","url":"https://stock-news.laohu8.com/highlight/detail?id=2660306364","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660306364?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:48","pubTimestamp":1787006906,"startTime":"0","endTime":"0","summary":"Cogstate Ltd ( ($AU:CGS) ) has provided an announcement. Cogstate Ltd, a provider of digital cognitive assessment solutions for global clinical tri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cogstate-lifts-profit-and-doubles-dividend-as-clinical-trials-revenue-surges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cogstate-lifts-profit-and-doubles-dividend-as-clinical-trials-revenue-surges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","VIG","BMED","NVIB","GDOC","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659983127","title":"This Healthcare Stock Could Jump Nearly 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659983127","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659983127?lang=en_us&edition=fundamental","pubTime":"2026-08-15 09:30","pubTimestamp":1786757400,"startTime":"0","endTime":"0","summary":"Medpace has carved out a niche helping smaller biotech companies navigate the complicated regulatory process. By Todd ChankoBy the time any of us stop by our local pharmacy to pick up a medication, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","LU0648000940.SGD","LU0029874061.USD","BK4137","BK4585","LU0130517989.USD","HEAL","LU0477156953.USD","LU1989764748.USD","LU1791710582.SGD","BK4581","LU0130102774.USD","LU0648001328.SGD","LU2065170008.USD","LU0882574055.USD","LU2065171402.SGD","NVIB","LU0980610538.SGD","LU1791710400.SGD","XBI","EKG","HCSG","LABU","XLV","LU1989764664.SGD","BK4530","IQV","LU1201861165.SGD","BK4588","LU0130518102.USD","LU2065171311.SGD","FTRE","LU1201861249.SGD","LU1261432733.SGD","MEDP","LU0477156797.USD","BK4121","LU0198837287.USD","LU2065169927.USD","LU0528227936.USD","LU0130103400.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126775","title":"Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126775?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:05","pubTimestamp":1786737900,"startTime":"0","endTime":"0","summary":"EB-003 Development Highlights:--  Continued advancing IND-enabling studies supporting the planned. submission of an Investigational New Drug  application for EB-003. --  Reported preclinical data demonstrating that EB-003 consistently. exhibited a non-hallucinogenic profile in a highly sensitive. --  Announced promising results from preclinical in vitro experiments. indicating no photoreactive potential for EB-003, further derisking its. continued development as a potential treatment of neuropsychiatric. --  Initiated genotoxicity studies to evaluate the potential for EB-003 to. interact with DNA and cause genetic mutations, a critical measure of. --  Secured U.S. Patent No. 12,605,361 pertaining to the Company's EVM301. Series of molecules being developed as potential treatments for mental","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4007","TM","ENVB","IDNA","BK4585","BK4604","HYLG","BK4588","BK4555","NVIB","BK4099","GDOC","MEDX","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141595","title":"Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141595","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141595?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP companion diagnostic i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345276/0/en/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BMED","ALLR","BK4503","LENZ","CDMO","BK4551","BK4023","BK4139","PLTM","BK4535","CLIA","BK4539","BK4007","GDOC","API","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659450421","title":"Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659450421","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659450421?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345223/24675/en/fate-therapeutics-initiates-potentially-registrational-reclaim-ln-clinical-trial-of-ft819-for-the-treatment-of-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","BK4022","HYLG","BK4139","BK4230","FATE","IDNA","MEDX","BK4077","LABU","SLE","CAR","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145865","title":"Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145865","media":"Dow Jones","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145865?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"US$9.5 million as of June 30, 2026, increased from US$4.1 million as of. -- Cash and cash equivalents nearly doubled to US$3.65 million, up from. -- Total shareholders' equity increased to US$6.09 million, up approximately. 19% from US$5.10 million at December 31, 2025, reflecting a strengthened. -- Working capital improved significantly to approximately US$1.66 million. as of June 30, 2026, up from approximately US$0.42 million at December. 31, 2025, indicating strengthened short-term liquidity and full coverage. -- Quick ratio of 1.19 as of June 30, 2026, compared to 1.06 as of December. divided by current liabilities), confirming robust liquidity even on a. December 31, 2025. Importantly, approximately 47% of current liabilities,items, reflecting the Company's strong balance sheet management.Reduced Cash Burn and Cost Discipline-- Total operating expenses decreased by 53% in the second quarter of 2026. compared to the same period in 2025, to US$2.29 million from US$4.85. -- General ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","BK4551","LU0795875169.SGD","LU0106831901.USD","LCDL","LU0210528500.USD","LU1244550221.USD","BK4585","LU0098860793.USD","LCIZ","LABU","LU1989772923.USD","LU1791710400.SGD","LCID","LU0006306889.USD","LU1244550494.USD","LU1732799900.SGD","LU1548497426.USD","TM","IAI","BK4516","LU1244550577.SGD","LU2023251221.USD","BK4581","EQR","LU1732800096.USD","LU0314104364.USD","LU1791710582.SGD","IND","LU0912757837.SGD","BK4099","LU0158827948.USD","NVIB","QNTM","LU0267386448.USD","LU0106261372.USD","BK4127","REZ","03160","LU2264538146.SGD","IE00B775SV38.USD","LU2111349929.HKD","LU1988902786.USD","KBWB","LU0053666078.USD","VMRK","LU2357305700.SGD","LU2089283258.USD","LU2133065610.SGD","LU0234570918.USD","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659195237","title":"Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659195237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659195237?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654920,"startTime":"0","endTime":"0","summary":"Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3345007/0/en/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BMED","LU2065732104.USD","MSLE","HYLG","PRGS","BK4139","GDOC","IDNA","IND","BK4097","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659627661","title":"CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659627661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659627661?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344920/0/en/camp4-reports-second-quarter-2026-financial-results-and-corporate-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","NVIB","MEDX","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","GDOC","IDNA","BK4585","BK4232","BK4139","BK4535","BK4539","IND","BK4568","R","BK4022","IVVD","MEDX","BK4551","BK4588","HYLG","BK4548","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CRBU","GNOM","TBXU","LD","CNCR","GDOC","BK4139","ORR","CAR","BK4585","MEDX","BK4195","IBBQ","LFSC","CR","BK4230","PFS","BK4539","IBB","FBT","NVIB","BK4161","BK4022","SYNB","BK4211","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152369","title":"PDS Biotech Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152369?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","ORR","BK4585","HYLG","IDNA","BK4581","XBI","PDS","BK4588","MEDX","BK4092","NVIB","BK4211","BK4195","PFS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}